Daniel E. Falk, Ph.D.

Biostatistics; Clinical trial design; medications development; Outcome measures

Dr. Daniel Falk is the Branch Chief of the Medications Development Branch (MDB) within the Division of Treatment and Recovery (DTR) at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). At NIAAA, he directs research on pharmacotherapy for alcohol use disorder (AUD) and novel methods for clinical trials, including the evaluation of new endpoints. Dr. Falk co-leads the NIAAA Alcohol Pharmacotherapy Evaluation Program (APEP) - a contract program which evaluates the efficacy and safety of novel and repurposed compounds to treat AUD in laboratory and randomized clinical trials. Dr. Falk is also the Coordinator of the NIAAA Data Archive, a large data repository over 400 NIAAA funded studies involving human subjects. Dr. Falk has authored a number of publications and presentations on a diverse set of alcohol-related topics, including pharmacotherapy to treat AUD, statistical methods and outcomes for alcohol clinical trials, psychiatric comorbidity of AUD, and correlates of alcohol use. Prior to joining NIAAA, he conducted epidemiologic research on AUD as a contractor for NIAAA. Dr. Falk received his Ph.D. in Clinical Psychology from the University of Miami.